Call Us + 33 1 84 88 31 00

Article R5121-143 of the French Public Health Code

For medicinal products containing radionuclides, in addition to the information provided for in article R. 5121-140, the labelling of the protective shielding provides all the explanations relating to the codes used on the vial and indicates, where applicable, the total or unit quantity of radioactivity for a given time and date as well as the number of capsules or, for liquids, the number of millilitres contained in the container. The…

Read More »

Article R5121-144 of the French Public Health Code

I.-The labelling of the medicinal products mentioned in 1° of II of article L. 5121-12 includes at least the following information: 1° The name of the medicinal product or, where appropriate, its code name or international non-proprietary name; 2° The name or corporate name and address of the company manufacturing the medicinal product; 3° The batch number; 4° The route and, if applicable, the method of administration of the medicinal…

Read More »

Article R5121-145 of the French Public Health Code

The labelling of the medicinal products mentioned in II of article L. 5121-12-1 includes at least the following information: 1° The name of the medicinal product or, where appropriate, its code name or international non-proprietary name; 2° The name or business name and address of the company; 3° The batch number; 4° The route and, where appropriate, the method of administration of the medicinal product; 5° The expiry date; 6°…

Read More »

Article R5121-146 of the French Public Health Code

The labelling and, where applicable, the package leaflet of the medicinal products referred to in article L. 5121-13 must bear the following information only: 1° Homeopathic medicinal product in clearly visible characters ; 2° The common name of the homeopathic stock or stocks with reference to the European pharmacopoeia or, failing that, the French pharmacopoeia, where this is included, followed by the degree of dilution. If the homeopathic medicinal product…

Read More »

Article R5121-146-1 of the French Public Health Code

In addition to the information provided for in articles R. 5121-138 and R. 5121-149, the labelling and package leaflet of traditional herbal medicinal products indicate that: 1° The product is a traditional herbal medicinal product with specified indications based exclusively on the age of use; 2° The user is invited to consult a doctor or a qualified health professional if symptoms persist during use of the medicinal product or if…

Read More »

Article R5121-146-2 of the French Public Health Code

Without prejudice to the provisions of Article R. 5132-15, the labelling of the immediate packaging and, if available, the outer packaging of the preparations mentioned in 1° to 3° of Article L. 5121-1 must bear, on a white background, the following information, written in such a way as to be easily legible, clearly understandable and indelible: 1° Particulars relating to the identification of the preparation : a) The name or…

Read More »

Article R5121-146-3 of the French Public Health Code

Ampoules or other small primary packaging on which it is impossible to include all the information provided for in Article R. 5121-146-2 may bear only the information provided for in a, c, d and h of 1° of Article R. 5121-146-2, in a, b and c of 2° of the same article, as well as : 1° Where the preparation contains up to three active substances, the common name or…

Read More »

Article R5121-148 of the French Public Health Code

The presence of an information leaflet for the user in the packaging of any medicinal product or product is compulsory, unless the information referred to in article R. 5121-149 appears directly on the outer packaging or the immediate packaging. It must be written in French, in terms that are easy for the user to understand and sufficiently legible, taking into account the results of consultation with groups of patients. It…

Read More »

Article R5121-149 of the French Public Health Code

The package leaflet is drawn up in accordance with the summary of product characteristics. It includes a standard text, expressly inviting patients to report any suspected adverse reaction to their doctor, pharmacist or any other health professional or directly to the regional pharmacovigilance centre, and specifying the various reporting methods available to them. It also includes, in order, the following information: 1° For the identification of the medicinal product or…

Read More »

Contact a French lawyer now

Contact a French Business Lawyer

Our French business lawyers are here to help.
We offer a FREE evaluation of your case.
Call us at +33 (0) 1 84 88 31 00 or send us an email.

Useful links

You have a question in French Business Law?

Our French business lawyers are here to help.
We offer a FREE evaluation of your case.
Call +33 (0) 1 84 88 31 00 or send us an email.

All information exchanged through this website will be communicated to lawyers registered with a French Bar and will remain confidential.